Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related DSW
Benzinga's Top Upgrades, Downgrades For May 24, 2017
25 Stocks Moving In Wednesday's Pre-Market Session
Related PFE
How Much The Opioid Epidemic Actually Costs The Non-User
The Current State Of The Breast Cancer Treatment Space
IBD 50 Stock Veeva Flies To Record High On 'Another Exceptional Quarter' (Investor's Business Daily)

Analysts at Sterne Agee downgraded DSW (NYSE: DSW) from Neutral to Underperform. The target price for DSW is set to $23. DSW's shares closed at $27.16 on Friday.

BMO Capital downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform. The target price for Pfizer has been lowered from $34 to $31. Pfizer's shares closed at $30.19 on Friday.

Analysts at Canaccord Genuity downgraded AcelRx Pharmaceuticals (NASDAQ: ACRX) from Buy to Hold. The target price for AcelRx Pharmaceuticals has been lowered from $16.00 to $8.00. AcelRx Pharmaceuticals' shares closed at $10.83 on Friday.

Deutsche Bank downgraded Lear (NYSE: LEA) from Buy to Hold. The target price for Lear has been raised from $100.00 to $103.00. Lear's shares closed at $99.00 on Friday.

Latest Ratings for DSW

DateFirmActionFromTo
May 2017SusquehannaUpgradesNegativeNeutral
May 2017BuckinghamDowngradesBuyNeutral
Mar 2017MizuhoDowngradesBuyNeutral

View More Analyst Ratings for DSW
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (DSW + ACRX)

View Comments and Join the Discussion!